The biopharmaceutical company is testing with multiple U.S. military branches at Northern Strike to provide Bexson’s BB106 ketamine therapy for pain management for contested environments.
Santa Barbara, Calif. — Bexson Biomedical, Inc., a biopharmaceutical company focused on enabling health delivery solutions through their novel formulation technology, SEVALENT™, announced that it will be field-testing the Company’s AKESO™ wearable device as part of Northern Strike, a military training and readiness exercise, this August.
Management believes AKESO™, a ruggedized version of the wearable infusion device utilizing SEVALENT™ technology, can provide rapid ketamine-based pain relief to soldiers in contested environments. In addition to the device’s lightweight and rugged durability, management believes its technology allows for the simplicity of use by both medical and non-medical military personnel which will greatly enhance efficiency of administration better serving our U.S. service men and women.
Northern Strike/Northern Agility is a joint exercise involving up to 10,000 service members from all 5 U.S.military branches. The exercise tests readiness of U.S. forces working in concert with invited NATO partners.
Operations take place in August of each year at multiple Michigan facilities, including the Alpena Combat Readiness Training Center and Camp Grayling Joint Maneuver Training Center.
The U.S. Military currently utilizes ketamine for pain management in austere and contested environments, andits use is described in current Tactical Combat Casualty Care guidelines (TCCC). These guidelines call for the use of ketamine to treat pain, primarily by intravenous (IV) administration.
Military medical and non-medical personnel will be trained to use Bexson’s device on the battlefield as a potential future alternative to cumbersome IV ketamine administration. Key to early development of this therapy will be verifying the user requirements in simulated battlefield conditions. Bexson engineers will be on hand to gain input on device utility, lessons learned from using it in field exercises, mission impact, and outcomes for the warfighter.
“While IV is an effective route of administration for drug delivery, there are major limitations and inefficiencies when used on the battlefield, and thus, we believe there is an urgent identifiable need for a medicine delivery platform that is faster and simpler for use in contested environments,” Gregg Peterson, Co-founder & CEO,Bexson Biomedical said. “We believe this device will be a game changer for the military, and we’re honored to be in involved this training exercise.”
Bexson Biomedical, Inc.
Bexson Biomedical, Inc. is a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health delivery. Bexson s proprietary formulation platform, SEVALENT™, can be applied to small molecules across a broad range of drug classes, enabling intravenous (IV) therapies to be delivered subcutaneously.
Bexson s lead therapy, BB106, is a low-dose ketamine treatment for post-operative pain management, a $36B global market and leading driver of opioid addiction. Additionally, management believes its BB106 therapy can be utilized to address various mental health indications.
Bexson Biomedical, Inc. Contact Information
Investor Relations please contact Matthew Pigeon Matthew@bexsonbiomedical.com
Press inquiries please contact Teresa Bigelow at teresa@spiral5.com
